MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Part of paid clinical trials in Beverly Hills, California.

Sponsor
Pfizer
Study ID
NCT04649359
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

Key Dates

Start date
Feb 2, 2021
Status verified
May 2026
Primary completion
Jun 17, 2022
Completion
Dec 31, 2026

Study Design

Enrollment
187 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Elranatamab (cohort A)
    BCMA-CD3 bispecific antibody
  • Experimental: Elranatamab (cohort B)
    BCMA-CD3 bispecific antibody

Primary Outcome Measure

Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria [ Time Frame: From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (up to approximately 16 months) ]

Locations (21)

FacilityCityStateZIPSite coordinators
Beverly Hills Cancer CenterBeverly HillsCalifornia90211-
Chao Family Comprehensive Cancer Center and Ambulatory CareIrvineCalifornia92612-
UCLA Hematology/Oncology ClinicLos AngelesCalifornia90095-
UC Irvine Health - Chao Family Comprehensive Cancer CenterOrangeCalifornia92868-
Baptist Hospital of MiamiMiamiFlorida33176-
Miami Cancer InstituteMiamiFlorida33176-
Blood and Marrow Transplant Group of GeorgiaAtlantaGeorgia30342-
Emory UniversityAtlantaGeorgia30322-
Winship Cancer Institute, Emory UniversityAtlantaGeorgia30322-
Northwestern Medical GroupChicagoIllinois60611-
Northwestern Memorial HospitalChicagoIllinois60611-
Loyola University Chicago performing research at Loyola University Medical CenterMaywoodIllinois60153-
Loyola University Medical CenterMaywoodIllinois60153-
Norton Women's and Children's HospitalLouisvilleKentucky40207-
Ochsner Clinic FoundationNew OrleansLouisiana70121-
Regional Cancer Care Associates, LLCHackensackNew Jersey07601-
Memorial Sloan Kettering Cancer Center - Investigational Drug Service PharmacyLong Island CityNew York11101-
Weill Cornell Medical College - New York Presbyterian HospitalNew YorkNew York10021-
Weill Cornell Medical College - New York Presbyterian HospitalNew YorkNew York10065-
St Francis Physician Services IncGreenvilleSouth Carolina29601-
Baylor Scott & White Research InstituteDallasTexas75204-

Find similar trials in Beverly Hills, CA

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Beverly Hills Cancer Center· Beverly Hills, CAChao Family Comprehensive Cancer Center and Ambulatory Care· Irvine, CAUCLA Hematology/Oncology Clinic· Los Angeles, CAUC Irvine Health - Chao Family Comprehensive Cancer Center· Orange, CABaptist Hospital of Miami· Miami, FLMiami Cancer Institute· Miami, FL

Related Studies